谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Arnon P Kater,Mark-David Levin,Julie Dubois,Sabina Kersting,Lisbeth Enggaard,Gerrit J Veldhuis,Rogier Mous,Clemens H M Mellink,Anne-Marie F van der Kevie-Kersemaekers,Johan A Dobber,Christian B Poulsen,Henrik Frederiksen,Ann Janssens,Ida Schjødt,Ellen C Dompeling,Juha Ranti,Christian Brieghel,Mattias Mattsson,Mar Bellido,Hoa T T Tran,Kazem Nasserinejad,Carsten U Niemann

The Lancet Oncology（2022）

引用 19|浏览34
暂无评分
关键词
refractory chronic lymphocytic leukaemia,venetoclax,disease-guided,open-label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要